Chronic Obstructive Pulmonary Disease | Decision Base | US | 2015
How Can Novel LABA/LAMA Combinations Differentiate Themselves in an Increasingly Crowded Market?
Treatment of chronic obstructive pulmonary disease (COPD) is dominated by bronchodilators, and polypharmacy is commonplace as patients’ COPD worsens. Although substantial opportunity exists for a disease-modifying therapy, development of new COPD therapies has focused instead on therapies that combine two bronchodilators in one inhaler. As the COPD marketplace becomes increasingly crowded with these fixed-dose combinations, emerging therapies will need to be clearly differentiated from competitors to experience substantial uptake.
Related Market Assessment Reports
Report
Uterine Fibroids – Current Treatment – Treatment Algorithms: Claims Data Analysis – Uterine Fibroids (US)
Treatment for uterine fibroids includes pharmacological approaches and surgical procedures. NSAIDs help alleviate the pain but do not reduce the fibroids’ size. Progestins (e.g., norethindrone,…
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (Including IBS Without Diarrhea) (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is classified into three subtypes:…
Report
Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, patients must…
Report
Amyotrophic Lateral Sclerosis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Amyotrophic lateral sclerosis (ALS) is a disorder of the central nervous system characterized by motor neuron degeneration. ALS causes progressive weakness and atrophy of the muscles and loss of…
